MedinCell secures $19Mn grant from Bill & Melinda Gates Foundation
Category: #business  | By Nikita Chaurasia  | Date: 2019-11-30 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

MedinCell secures $19Mn grant from Bill & Melinda Gates Foundation

MedinCell S.A., a French pharmaceutical company, has signed an agreement with the Bill & Melinda Gates Foundation for an additional $19 million that would be offered over the next four years. The arrangement focuses on funding preclinical activities along with a Phase 1 clinical study for mdc-WWM, the injectable six-month bioresorbable contraceptive. 

According to reliable sources, the grant is designed to take care of the project costs via advanced installments. Depending on the developments of the study and on options chosen, a maximum of $11.75 million can be funded over the next year which contains the first tranche of $4.75 million that needs to be paid first following the remaining $7.25 million.

Earlier in 2017, the Gates Foundation had granted a $3.5 million funding to back the formulation research phase. Meanwhile, the French pharma possesses the global marketing rights of the product, including in the U.S., where the contraceptive market has garnered over $5 billion in 2018.

In fact, LARC (Long-acting reversible contraceptives) alone held 28% of this market, valuing over $1.4 billion. The mdc-WWM product can secure an important chunk of this LARC market. Also, it has the potential to further easen the acceptance of this contraception.

Reportedly, MedinCell had prior made headlines when it collaborated with Cornerstone Animal Health to advance a variety of state-of-the-art long-acting injectable veterinary items using the its BEPO® proprietary technology.

Sources cite that Cornerstone would head the funding regulatory development and either commercialize or license the item. The agreement focuses on supporting the financial capability of BEPO® in animal health to advance MedinCell’s profitability as well as to make long-term sustainable profits. Moreover, the JV is designed to reduce the impact on the biotech’s resources and cash.

For the uninitiated, Cornerstone Animal Health is an Animal Health commercialization group based in the United States. It was created by seasoned veterans of the industry with majority of the founders being former executives of iconic firms like Merck Animal Health, Merial or Pfizer Animal Health (Zoetis).
 

Source Credit: https://www.businesswire.com/news/home/20191128005494/en/Medincell-Receives-19-Million-Grant-mdc-WWM-Program

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...

Attero aims to increase recycling capacity, plans for IPO in 2025

Attero aims to increase recycling capacity, plans for IPO in 2025

By Nikita Chaurasia

Attero Recycling, a firm that recycles electronic waste, is aiming to launch an initial public offering (IPO) in 2025, according to its Co-Founder and CEO Nitin Gupta. As per Gupta, the company is currently debating whether to list its shares in I...